Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.43 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123516 | 0.88 | ERN1 (0.43) | RAB9ANPC1ERN1SMN1; SMN2HPGD | |
| SCHEMBL2206333 | 0.78 | HPGD (0.51) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL5838441 | 0.78 | CNR1 (0.56) | HTR2CRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL7118397 | 0.77 | ALDH1A1 (0.43) | RAB9ANPC1SMN1; SMN2TP53HPGD | |
| SCHEMBL7119468 | 0.76 | EGFR (0.63) | — | |
| SCHEMBL7667538 | 0.75 | HPGD (0.38) | RAB9ANPC1SMN1; SMN2TP53MAPK1 | |
| SCHEMBL5014381 | 0.75 | SMN1; SMN2 (0.64) | HTR2CRAB9ANPC1ERN1SMN1; SMN2 | |
| SCHEMBL5014387 | 0.74 | ERN1 (0.47) | HTR2CRAB9ANPC1ERN1SMN1; SMN2 | |
| SCHEMBL7123648 | 0.71 | GRM5 (0.41) | RAB9ANPC1GRM5 | |
| SCHEMBL7123672 | 0.70 | MCHR1 (0.41) | RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-6492383-B1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | PFIZER INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162795-A1 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents | TYMP, DPYD, HPRT1 | HTR2C 3112/4885RAB9A 2707/4885NPC1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.